Molecular Dynamics Sample Clauses

Molecular Dynamics. Molecular dynamics [13, 14] is a well established method to study thermodynamic properties of complex many-particle systems at finite temperature. The idea is to evolve in time the atoms in the system according to the classical equations of motion to closely match the microscopic evolution of the system. Macroscopic thermodynamic properties of the system can then be computed based on the ergodic hypothesis that the statistical ensemble averages are equal to time averages along the trajectory of the system. Similar analyses can be performed with ab-initio molecular dynamics, in which the explicit calculation of the electronic structure is used to compute potential energies and forces [15]. A significant advantage of ab-initio molecular dynamics is that no parameterization of an empirical potential is needed and that systems can be simulated when unexpected chemical events take place. In this section a brief overview of two different AIMD methods used in this thesis will be given, the Car-Xxxxxxxxxx Molecular Dynamics, used in the CPMD program [16], and the Born- Xxxxxxxxxxx Molecular Dynamics, used in the CP2K software package [17].
AutoNDA by SimpleDocs
Molecular Dynamics. Dynamical simulations are usually performed by classical mechanics and involve the integration of Newtxx'x xxxations of motion for a suitable prepared system. Semiclassical or quantum dynamics can be introduced into the
Molecular Dynamics. 26 2.2.1 Introduction . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 26 2.2.2 Ergodicity in MD . . . . . . . . . . . . . . . . . . . . . . . . . . . . 26 2.2.3 Velocity-Verlet Algorithm . . . . . . . . . . . . . . . . . . . . . . . 27 2.2.4 Thermostat . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 27 2.2.5 Classical Force Fields . . . . . . . . . . . . . . . . . . . . . . . . . 29 2.2.6 Xxxxxxx-Xxxxx Potentials . . . . . . . . . . . . . . . . . . . . . . . 29 2.2.7 Xxxxxxxxxx-Xxxxx (SW) Potentials . . . . . . . . . . . . . . . . . . . 30 2.2.8 Xxxxxxx and Xxxxxxx Potentials . . . . . . . . . . . . . . . . . . . . 31 2.3 First-Principles Molecular Dynamics . . . . . . . . . . . . . . . . . . . . . 32 2.4 Beyond the classical calculations . . . . . . . . . . . . . . . . . . . . . . . 33 2.4.1 QM/MM Embedding . . . . . . . . . . . . . . . . . . . . . . . . . . 33 2.4.2 LOTF Molecular dynamics 35 2.4.3 Summary 38 3 Fracture Modelling 39 3.1 Introduction 39 3.2 Xxxxxxxx’x Criterion 39 3.3 Velocity of the Crack Propagation 41 3.4 Results: Xxxxxxx Xxxx Breaking 45 3.5 Summary 49 4 Background- II 50

Related to Molecular Dynamics

  • Cellular Phone Employer shall provide Employee with a cellular phone for his use in performing his responsibilities with Employer. In the alternative, Employer shall pay Employee’s cellular phone expense.

  • Collaboration Management Promptly after the Effective Date, each Party will appoint a person who will oversee day-to-day contact between the Parties for all matters related to the management of the Collaboration Activities in between meetings of the JSC and will have such other responsibilities as the Parties may agree in writing after the Effective Date. One person will be designated by Merck (the “Merck Program Director”) and one person will be designated by Moderna (the “Moderna Program Director,”) together will be the “Program Directors”. Each Party may replace its Program Director at any time by notice in writing to the other Party. Any Program Director may designate a substitute to temporarily perform the functions of that Program Director by written notice to the other Party. The initial Program Directors will be: For Moderna: [***] For Merck: [***]

  • Technology Discoveries, innovations, Know-How and inventions, whether patentable or not, including computer software, recognized under U.S. law as intellectual creations to which rights of ownership accrue, including, but not limited to, patents, trade secrets, maskworks and copyrights developed under this Agreement.

  • Baxter and Nexell shall cooperate in any action taken by a third party solely involving a nullity action, opposition, reexamination or any other action taken by such third party alleging the invalidity or unenforceability of any Licensed Intellectual Property. Both parties agree to share equally in the cost of the defense of such Licensed Intellectual Property.

  • Collaboration We believe joint effort toward common goals achieves trust and produces greater impact for L.A. County’s youngest children and their families.

  • Commercialization Intrexon shall have the right to develop and Commercialize the Reverted Products itself or with one or more Third Parties, and shall have the right, without obligation to Fibrocell, to take any such actions in connection with such activities as Intrexon (or its designee), at its discretion, deems appropriate.

  • Commercialization Plans As soon as practicable after formation of the JCC (following Acucela’s exercise of an Opt-In Right under Section 3.1), the JCC shall prepare and approve the initial Commercialization Plan for Commercialization of the Licensed Product for the Initial Indication in the Initial Formulation (and, if applicable, any New Formulation or Other Indication Product) in the Territory. The Parties shall use Commercially Reasonable Efforts to ensure that such initial Commercialization Plan for Commercialization of the Licensed Product for the Initial Indication in the Initial Formulation is consistent with the general Commercialization Plan outline set forth in Exhibit C attached hereto and incorporated herein (the “General Commercialization Plan Outline”). The JCC shall prepare and approve a separate Commercialization Plan for Commercialization of Licensed Product for the Initial Indication in the Initial Formulation in the Territory and for Commercialization of each Other Indication Product and New Formulation (if any) in the Territory, and shall update and amend each Commercialization Plan not less than annually or more frequently as needed to take into account changed circumstances or completion, commencement or cessation of Commercialization activities not contemplated by the then-current Commercialization Plan. Amendments and revisions to the Commercialization Plan shall be reviewed and discussed, in advance, by the JCC, and Otsuka agrees to consider proposals and suggestions made by Acucela regarding amendments and revisions to the Commercialization Plan. Any amendment or revision to the Commercialization Plan that provides for an increase or decrease in the number of FTEs for any Phase 3b Clinical Trials or Post-Approval Studies as compared to the previous version of the Commercialization Plan, or that provides for addition or discontinuation of tasks or activities as compared to the previous version of the Commercialization Plan, or that moves forward the timetable for activities reflected in the Commercialization Plan, shall provide for a reasonable ramp-up or wind-down period, as applicable, to accommodate a smooth and orderly transition of Commercialization activities to the amended or revised Commercialization Plan. Each Commercialization Plan shall identify the goals of Commercialization contemplated thereunder and shall address Commercialization (including Co-Promotion) activities related to the Licensed Product (including, if applicable, any Other Indication Product), including:

  • Manufacturing Technology Transfer With respect to each Technology Transfer Product, upon AbbVie’s written request after the Inclusion Date for the Included Target to which such Technology Transfer Product is Directed, Morphic shall effect a full transfer to AbbVie or its designee (which designee may be an Affiliate or a Third Party manufacturer) of all Morphic Know-How and Joint Know-How relating to the then-current process for the Manufacture of such Technology Transfer Product (the “Manufacturing Process”) and to implement the Manufacturing Process at facilities designated by AbbVie (such transfer and implementation, as more fully described in this Section 5.3, the “Manufacturing Technology Transfer”). To assist with the Manufacturing Technology Transfer, Morphic will make its personnel reasonably available to AbbVie during normal business hours for up to [***] FTE hours with respect to each Included Target (in each case, free of charge to AbbVie) to transfer and implement the Manufacturing Process under this Section 5.3. Thereafter, if requested by AbbVie, Morphic shall continue to perform such obligations; provided, that AbbVie will reimburse Morphic for its full-time equivalent (FTE) costs (for clarity, in excess of [***] FTE hours) and any reasonable and verifiable out-of-pocket costs incurred in providing such assistance. CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE IT IS NOT MATERIAL AND WOULD LIKELY CAUSE COMPETITIVE HARM TO THE COMPANY IF PUBLICLY DISCLOSED.

  • Cellular Telephone Executive shall receive reimbursement for reasonable expenses associated with Executive's use of a cellular telephone in performing his services.

Time is Money Join Law Insider Premium to draft better contracts faster.